New to Stratech’s offering is a range of induced pluripotent stem (iPS) and progenitor cells for preclinical drug discovery.
Cellular Engineering Technologies (CET) is a biotechnology company specialising in commercial regenerative and personalised medicine, cancer biology and cell-based assays. They are a leading provider of iPS cells derived from normal human volunteers and patients with various clinical conditions. With their novel technologies, CET have created iPS cells from a variety of target cells and from patients over a wide age range, with diseases that are generally resistant to iPS transformation.
CET has also developed scalable, proprietary technology to isolate personalised human cells from skin, human airways and from the gastrointestinal tract using minimally invasive approaches.
Cell isolation is currently focused on the following disease platforms:
- Rare Genetic (Orphan) Diseases
- Chronic Lung Disease
- Degenerative Psychiatric and Neurological Diseases
- Degenerative Muscular Diseases
- Cancer
In addition, CET develop media optimised for different cell types and provide contract research on stem cells obtained from human non-embryonic sources, such as adipose tissue, bone marrow, Wharton’s jelly, umbilical cord blood, and placentas.
--------------------------------------------------------------------
Where can I find more information about CET?
Visit the manufacturer page at www.stratech.co.uk/celleng-tech, email info@stratech.co.uk or call +44 (0) 1638 782600.
Stratech Scientific is a distributor of high quality, competitively priced, reliable products for research laboratories throughout the UK and Europe. Please contact us to find out which ranges we can supply in your country.
--------------------------------------------------------------------
View company site